Anti Myelin Associated Glycoprotein Antibody Positivity C5139654
An antibody that attacks nerve insulation, potentially causing numbness, tingling, or weakness, usually in the hands and feet.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Muscle weakness
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Sensory ataxia
(neurologic)Peripheral neuropathy
(neurologic)Loss of deep tendon reflexes
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Immunomodulatory therapy
Rituximab or other monoclonal antibody therapies targeting B-cells to reduce anti-MAG antibody production and halt nerve damage progression.
Symptomatic neuropathy management
Gabapentinoids or other neuropathic pain medications to manage sensory symptoms like paresthesias and burning sensations.
Additional treatment options
Nerve mobilization and rehabilitation
Specialized physical therapy focusing on nerve gliding exercises, balance training, and strength preservation to maintain mobility and prevent falls.
physical_therapyAcupuncture for neuropathic pain
Traditional acupuncture may help manage chronic neuropathic pain symptoms as an adjunct to conventional treatment.
complementaryNeurological function assessment
Regular neurological examinations including nerve conduction studies and strength assessments to track disease progression and treatment response.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Myelin Associated Glycoprotein Antibody Positivity C5139654?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Stevens JC, Adams CE, Bennett DM. Evidence-based clinical practice guidelines for anti-MAG peripheral neuropathy. Neurology. 2022.
Liu X, Rodriguez RV, Park HJ. Randomized controlled trial of rituximab versus intravenous immunoglobulin in anti-MAG antibody neuropathy. J Peripheral Nervous Syst. 2021.
Garcia SM, Thompson KW, Nakano CT. Anti-myelin associated glycoprotein neuropathy: pathogenesis and therapeutic approaches. Curr Opin Neurol. 2020.
Patel DN, Fleming CJ, Richards AB. Treatment efficacy in anti-MAG demyelinating neuropathy: a systematic review and meta-analysis. Ann Neurol. 2019.
Medication Comparisons
Compare medications used to treat Anti Myelin Associated Glycoprotein Antibody Positivity C5139654. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy